Contributions
Abstract: PB1918
Type: Publication Only
Background
Acute myeloid leukemia (AML) with myelodysplasia-related changes (MRC) is usually classified associated to worse clinical course and poor prognosis compared other AML subtypes. Differences between treatment modalities according to age, and the response to treatment, would help to provide specific anti-AML treatment in this difficult scenario.
Aims
The objetive of this study is analyze the clinical features and course of patients with AML with MRC, in order to evaluate the impact of different therapeutic regimens in this subgroup.
Methods
We report an unicentric retrospective study of 76 patients with AML with MRC, over the past ten years in a single institution in Spain. We analyzed the overall survival (OS) among the subgroup of patients with over or under 65 years, and the different types of treatment that has been offered.
Results
Median age was 69 years with a male predominance, and 66% was preceded by a known myelodysplastic syndrome with a median interval of 18 months to progress to AML. The more frequent genetic abnormalities in descending order were trisomies, del(5q), and del(7q)/-7. The patients aged >65 and <65 were 70% and 30%, respectively. The patients aged >65 received DNA hypomethylating agents (40%), anthracycline-cytarabine combinations (9%), low-dose cytarabine or hydroxyurea (17%), and supportive measures (34%). The patients aged <65 received induction chemotherapy with anthracycline-cytarabine combinations so as to continue with post-consolidation management with allogenic transplantation, but the 44% died over the induction chemotherapy (OS: 2.2 months). The OS in patients aged <65 was 20,2 months in chemotherapy plus allogenic transplantation. The OS in patients aged >65 was 10,3 months in the group of anthracycline-araC combinations, 3,81 months in the DNA hypomethylating agents group, 2,8 months in the low-dose of AraC/hydroxiurea, and 0,5 months in supportive measures group.
Conclusion
The AML with MRC patients is a group with difficult treatment decisions and poor prognosis, in whom only the chemotherapy plus allogenic transplantation treatment manage long-term survival. In patients aged >65, there is not a significant difference among groups, although the chemotherapy with anthracycline-cytarabine seems to reach a better OS versus other available treatments.
Session topic: 10. Myelodysplastic syndromes - Clinical
Keyword(s): Myelodysplasia, Acute Myeloid Leukemia
Abstract: PB1918
Type: Publication Only
Background
Acute myeloid leukemia (AML) with myelodysplasia-related changes (MRC) is usually classified associated to worse clinical course and poor prognosis compared other AML subtypes. Differences between treatment modalities according to age, and the response to treatment, would help to provide specific anti-AML treatment in this difficult scenario.
Aims
The objetive of this study is analyze the clinical features and course of patients with AML with MRC, in order to evaluate the impact of different therapeutic regimens in this subgroup.
Methods
We report an unicentric retrospective study of 76 patients with AML with MRC, over the past ten years in a single institution in Spain. We analyzed the overall survival (OS) among the subgroup of patients with over or under 65 years, and the different types of treatment that has been offered.
Results
Median age was 69 years with a male predominance, and 66% was preceded by a known myelodysplastic syndrome with a median interval of 18 months to progress to AML. The more frequent genetic abnormalities in descending order were trisomies, del(5q), and del(7q)/-7. The patients aged >65 and <65 were 70% and 30%, respectively. The patients aged >65 received DNA hypomethylating agents (40%), anthracycline-cytarabine combinations (9%), low-dose cytarabine or hydroxyurea (17%), and supportive measures (34%). The patients aged <65 received induction chemotherapy with anthracycline-cytarabine combinations so as to continue with post-consolidation management with allogenic transplantation, but the 44% died over the induction chemotherapy (OS: 2.2 months). The OS in patients aged <65 was 20,2 months in chemotherapy plus allogenic transplantation. The OS in patients aged >65 was 10,3 months in the group of anthracycline-araC combinations, 3,81 months in the DNA hypomethylating agents group, 2,8 months in the low-dose of AraC/hydroxiurea, and 0,5 months in supportive measures group.
Conclusion
The AML with MRC patients is a group with difficult treatment decisions and poor prognosis, in whom only the chemotherapy plus allogenic transplantation treatment manage long-term survival. In patients aged >65, there is not a significant difference among groups, although the chemotherapy with anthracycline-cytarabine seems to reach a better OS versus other available treatments.
Session topic: 10. Myelodysplastic syndromes - Clinical
Keyword(s): Myelodysplasia, Acute Myeloid Leukemia